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ABSTRACT
Objective To establish whether a novel accelerated
diagnostic protocol (ADP) for suspected acute coronary
syndrome (ACS) could successfully identify low-risk
patients suitable for discharge after a single high-
sensitivity troponin T (hs-cTnT) taken at presentation to
the emergency department. We also compared the
diagnostic accuracy of this ADP with strategies using
initial undetectable hs-cTnT.
Methods This prospective observational study
evaluated the ability of the Triage Rule-out Using high-
Sensitivity Troponin (TRUST) ADP to identify low-risk
patients with suspected ACS. The ADP incorporated a
single presentation hs-cTnT of <14 ng/L, a non-
ischaemic ECG and a modiﬁed Goldman risk score.
Diagnostic performance of the ADP was compared with
the detection limit cut-offs of hs-cTnT (<5 ng/L and
<3 ng/L). The primary end point was fatal/non-fatal
acute myocardial infarction (AMI) within 30 days.
Results 960 participants were recruited, mean age
58.0 years, 80 (8.3%) had an AMI. The TRUST ADP
classiﬁed 382 (39.8%) as low-risk with a sensitivity for
identifying AMI of 98.8% (95% CI 92.5% to 99.9%).
hs-cTnT detection limits (<5 ng/L and <3 ng/L) had a
sensitivity of 100% (94.3 to 100) and 100% (94.4 to
100), respectively. The TRUST ADP identiﬁed more
patients suitable for early discharge at 39.8% vs 29.3%
(<5 ng/L) and 7.9% (<3 ng/L) (p<0.001) with a lower
false-positive rate for AMI detection; speciﬁcity 43.3%
(95% CI 42.7% to 43.4%) vs 32.0% (95% CI 31.5%
to 32.0%) and 8.6% (95% CI 8.1% to 8.6%),
respectively.
Conclusions The TRUST ADP, which incorporates
structured risk-assessment and a single presentation hs-
cTnT blood draw, has potential to allow early discharge
in 40% of patients with suspected ACS and has greater
clinical utility than undetectable hs-cTnT strategies.
Trial registration number ISRCTN No. 21109279.
INTRODUCTION
Patients with suspected acute coronary syndrome
(ACS) make up to 10% of all emergency depart-
ment (ED) attendances and 25% of acute hospital
admissions.1 Current guidelines recommend two
serial measurements of non-high-sensitivity tropo-
nin between 6 h and 12 h after patient presentation
to the ED.2 As a result, the majority of patients
require prolonged assessment prior to safe dis-
charge despite the fact that only 15–25% of these
patients have a ﬁnal diagnosis of ACS.1
Consensus reports suggest that high-sensitvity
troponin (hs-cTn) assays may be used to reduce
door-to-discharge times by using serial testing over
3–6 h.3 Investigators have reduced blood draw
times further by incorporating structured clinical
risk assessment protocols with hs-cTn,4 or analys-
ing δ change over time.5 Despite successfully identi-
fying between 40% and 60% of low-risk patients,
these algorithms still require serial testing of hs-cTn
which will delay discharge from the ED. This delay
may be associated with signiﬁcant healthcare costs,6
and contribute to ED overcrowding.
To address these issues, several studies have
investigated the effectiveness of a single undetect-
able hs-cTn value taken at presentation to the ED
in identifying those at very low risk of acute myo-
cardial infarction (AMI).7–9 Despite demonstrating
promising results as a rule-out strategy for AMI,
this protocol has not been recommended by expert
guidelines due to concerns over assay analytical
interference and poor test speciﬁcity.3 Therefore, a
clinically applicable protocol that allows the dis-
charge of a signiﬁcant proportion of patients after
just a single hs-cTn blood draw at presentation
remains an attractive yet elusive goal.
Using binary hs-cTn results alone to guide dis-
charge decisions fails to use a wealth of clinical
information available to treating physicians. The
Goldman risk score10 uses simple variables that are
immediately available to the ED physician and are
derived from the history, examination and ECG
ﬁndings. Since its inception, the score has been
modiﬁed to improve physician decision making in
the identiﬁcation of low-risk patients. This has led
to improved use of hospital resources.11 Despite
achieving the highest level of evidentiary support
for use in ED patients with chest pain the modiﬁed
Goldman (m-Goldman) risk score remains untested
as a discharge tool in combination with a single
presentation hs-cTn.
The Triage Rule-out Using high-Sensitivity
Troponin (TRUST) study’s primary aim was to
establish whether a novel accelerated diagnostic
protocol (ADP) for patients with suspected ACS
consisting of hs-cTn, a non-ischaemic ECG and the
m-Goldman score, could successfully identify
low-risk patients suitable for discharge after a
single blood draw at presentation to the ED.
Secondary aims were to compare the diagnostic
accuracy of the ADP with strategies using initial
undetectable hs-cTnT levels.
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METHODS
This prospective observational clinical trial was designed to
assess the predeﬁned TRUSTADP. The protocol was designed to
be truly pragmatic in order to enhance the widespread applic-
ability of the study results12; with attending clinicians perform-
ing m-Goldman risk scores, rostered clinical (not research) staff
undertaking blood sampling, real-time sample processing and
24/7 recruitment. The study was designed using the Standards
for Reporting Diagnostic Accuracy.13 and approved by the UK
National Research Ethics Service. All participants provided
written informed consent. The TRUST study was registered
with the Controlled Trials Database (ISRCTN No. 21109279)
and complies with the Declaration of Helsinki.
Study setting, recruitment and data collection
Poole NHS Foundation Trust is a UK District General Hospital,
its ED has approximately 62 000 new patient attendances per
year. Patients with suspected ACS are managed according to the
local hospital protocol, which involves risk assessment by ED
physician staff using the m-Goldman risk score and blood
drawn for hs-cTnTat 6 h after presentation. As part of the study
protocol, blood was also taken at presentation for hs-cTnT ana-
lysis. While historical clinical protocols, at the time of this study,
did not include troponin measurement at presentation, this had
the beneﬁt of ensuring that treating physicians were blinded to
the initial hs-cTnT result to avoid selection bias.14
The ﬁfth generation Roche ELECSYS hs-cTnT assay (Roche,
Switzerland), which has a limit of detection (lowest analyte con-
centration likely to be reliably distinguished from the limit of
blank at which detection is feasible) of 5 ng/L, limit of blank
(highest apparent analyte concentration expected to be found
when replicates of a blank sample containing no analyte are tested)
of 3 ng/L, 99th centile of 14 ng/L and 10% coefﬁcient of variation
of <10% at 9 ng/L, was used for research (presentation) and refer-
ence (6-h) samples. During initial assessment clinical staff drew
blood for routine admission samples and an additional 3.5 mL of
whole blood in a prelabelled study-speciﬁc serum settling tube for
hs-cTnTanalysis. All serum samples were tested in real time.
Consecutive patients attending the ED with suspected ACS were
prospectively screened from July 2012 to August 2013. Patients
were included if they were at least 18 years of age and had at
least 5 min of chest pain suggestive of ACS, and for whom the
attending physician determined inpatient evaluation was required.
Possible cardiac symptoms included acute chest, epigastric, neck,
jaw or arm pain, or discomfort or pressure without an apparent
non-cardiac source, in accordance with the American Heart
Association case deﬁnitions.15 Patients were excluded if any of the
following were present: ST-segment elevation myocardial infarc-
tion or left bundle branch block not known to be old, ECG
changes diagnostic of ischaemia (STsegment depression ≥1 mm or
T-wave inversion consistent with the presence of ischaemia),2
arrhythmias (new-onset atrial ﬁbrillation, atrial ﬂutter, sustained
supraventricular tachycardia, second-degree or complete heart
block, or sustained or recurrent ventricular arrhythmias), hs-cTnT
not suitable for analysis (eg, haemolysis), age ≥80 years, atypical
symptoms in the absence of chest discomfort, a clear non-ACS
cause for chest pain was found at presentation (eg, pulmonary
embolism, pneumonia, aortic dissection), another medical condi-
tion requiring hospital admission, refusal or inability to give
informed consent, non-English speaking, pregnancy, renal failure
requiring dialysis or inability to be contacted after discharge.
Data were collected prospectively using a published data dic-
tionary.16 Attending ED clinicians completed the m-Goldman
risk score on a predesigned clinical report form. Follow-up was
undertaken by independent review of hospital electronic patient
records, summary of health records from the patient’s general
practitioner (GP) obtained at least 6 months after attendance
and a national clinical records search (which identiﬁes death).
The ethics committee did not grant permission for direct
patient contact as they felt that comprehensive follow-up data
relating to adverse events could be obtained accurately through
GP records. This is because in the UK, GPs hold comprehensive
records for individuals relating to primary, secondary and ter-
tiary care. GP records have been demonstrated to be more
accurate at reporting hospital admissions, including those for
cardiac related events, than patients.17 GPs were therefore
requested to provide all information regarding presentation to
other institutions with chest pain, cardiology outpatient review
and cardiac testing, including angiography with or without
intervention. Where a participant had not attended hospital
follow-up and/or a GP had failed to provide a health record/not
GP-registered, the patient was regarded as lost to follow-up.
Index tests
The primary index test was the TRUST ADP (table 1), this
deﬁned a patient as ‘low-risk’ if all of the following conditions
were satisﬁed at presentation: a m-Goldman Score of 0 or 1, a
non-ischaemic ECG and a single central laboratory hs-cTnT of
<14 ng/L at presentation.
Secondary index tests were the detection limits for hs-cTnT
(5 ng/L and 3 ng/L) and non-ischaemic ECG at presentation.
Outcome measures
The primary end point was the presence of fatal or non-fatal
AMI occurring within 30 days of hospital attendance (including
the index visit).
The presence of AMI was deﬁned according to the Third
Universal Deﬁnition of MI which states that a rise and/or fall in
Table 1 The Modified Goldman Score and the TRUST accelerated
diagnostic protocol (ADP)
Modified Goldman risk score 1 point for each variable present
Typical new-onset chest pain at rest
Pain the same as previous myocardial
infarction
Pain not relieved by glyceryl trinitrate
(GTN) spray within 15 min
Pain lasting more than 60 min
Pain occurring with increasing frequency
Hypotension (systolic blood pressure
<100 mm Hg)
Acute shortness of breath
Pain within 6 weeks of a myocardial
infarction or revascularisation
Modified Goldman total
Trust ADP
Low risk* (Suitable for discharge) 1. Modified Goldman score ≤1
2. Non-ischaemic ECG
3. Presentation high-sensitivity
troponin T <14 ng/L
Not low risk 1. Modified Goldman score >1
2. Ischaemic ECG
3. Presentation high-sensitivity
troponin T ≥14 ng/L
*Safety point: protocol not validated in age ≥80 years.
TRUST, Triage Rule-out Using high-Sensitivity Troponin.
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troponin, with at least one value above the 99th centile value in
the context of a patient with ischaemic symptoms or signs (ECG
changes or imaging evidence) would satisfy the diagnosis.18
Based on current consensus guidance for hs-cTn assays, a rise or
fall of 20% (δ) was considered statistically signiﬁcant and con-
sistent with a diagnosis of AMI.3 Adjudication of the primary
end point was carried out by two local cardiologists blinded to
the m-Goldman score but who had access to the clinical record,
ECG and serial hs-cTnT results. If a troponin result was above
the 99th centile value and a non-ischaemic cause of troponin
elevation was identiﬁed this was considered by the adjudicating
cardiologist in accordance with expert consensus.19
The presence of major adverse cardiac events (MACEs) occur-
ring within 30 days of hospital attendance (including the index
visit) was a secondary outcome measure. MACE included: death
due to ischaemic heart disease, cardiac arrest, urgent revasculari-
sation, cardiogenic shock, ventricular arrhythmia, high-degree
atrioventricular block needing intervention and AMI. MACE
was deﬁned according to previous large scale studies assessing
the safety of rapid discharge protocols.4 20 21
Figure 1 Participant recruitment ﬂow chart. The 132 patients who missed the consent process were similar in age, gender, risk factors and
m-Goldman scores (p>0.05 for all). ADP, accelerated diagnostic protocol; AMI, acute myocardial infarction; TRUST, Triage Rule-out Using
high-Sensitivity Troponin.
Table 2 Patient characteristics
Total (N=960)
Fatal/non-fatal AMI
positive at 30 days (N=80)
TRUST ADP intermediate/high
risk (N=578)
TRUST ADP low risk
(N=382)
Age, years (Mean±SD) 58.0±13.3 63.3±10.6 60.4±12.8 55.6±19.4
Sex (% male) 565 (58.9) 53 (66.3) 360 (62.3) 205 (53.7)
Ethnicity (% British Caucasian) 914 (95.2) 72 (90.0) 549 (95.0) 365 (95.5)
Risk factors N (%)
Hypertension 452 (47.1) 59 (73.8) 319 (55.2) 123 (34.8)
Diabetes 164 (17.1) 20 (25.0) 124 (21.4) 40 (10.5)
Dyslipidaemia 635 (66.1) 63 (78.6) 429 (74.2) 206 (53.9)
Smoking current 231 (24.1) 19 (23.8) 129 (22.3) 102 (26.7)
Smoker ex 343 (35.1) 30 (37.5) 229 (39.6) 114 (29.8)
Family history of coronary artery disease 354 (36.9) 29 (36.3) 215 (37.2) 139 (36.4)
Medical history
Angina 251 (26.1) 29 (36.3) 207 (35.8) 44 (11.5)
Myocardial infarction 204 (21.3) 26 (32.5) 174 (30.1) 30 (7.9)
Percutaneous coronary intervention 183 (19.1) 22 (27.5) 146 (25.3) 37 (9.7)
Congestive cardiac failure 30 (3.1) 4 (5.0) 25 (4.3) 5 (1.3)
Atrial arrhythmia 119 (12.4) 8 (10.0) 86 (14.9) 33 (8.6)
Stroke 63 (6.6) 5 (6.3) 45 (7.7) 18 (4.7)
Coronary artery bypass graft 50 (5.2) 7 (8.8) 41 (7.1) 9 (2.4)
Baseline medications
Aspirin 361 (37.6) 40 (50.0) 276 (47.8) 85 (22.3)
Clopidogrel 112 (11.7) 8 (10.0) 84 (14.5) 28 (7.3)
β blocker 281 (29.3) 25 (31.3) 210 (36.3) 71 (18.6)
ACE inhibitor 272 (28.3) 29 (36.3) 195 (33.7) 77 (20.2)
Statin 369 (38.4) 37 (46.3) 276 (47.8) 93 (24.3)
Median length of hospital stay (h)±IQR 18.8±32.4 107.5±110.3 22.4±62.0 14.0±11.9
ADP, accelerated diagnostic protocol; AMI, acute myocardial infarction; TRUST, Triage Rule-out Using high-Sensitivity Troponin.
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Statistical analysis
Baseline characteristics of the study population were analysed
with conventional group descriptive statistics. Diagnostic proto-
col results and outcome status were cross-tabulated to permit
calculation of sensitivity, speciﬁcity, negative predictive value
(NPV), positive predictive value, positive likelihood ratio and
negative likelihood ratio. Statistical signiﬁcance was evaluated
using McNemar’s test. All statistical analysis was carried out
using SPSS V.20.
RESULTS
Nine hundred and sixty-four consenting patients were recruited
(ﬁgure 1), Four patients were lost to follow-up (health records
pertaining to presence of outcome measures unobtainable)
meaning that 99.6% were successfully monitored for 30 days.
However, no patient lost to follow-up died within 30 days of
attendance. Participants were predominantly white, older men
who commonly had risk factors for coronary artery disease
(table 2). Of the patients 80/960 (8.3%) had a primary outcome
event (fatal or non-fatal AMI) and 97/960 (10.1%) had a
MACE within 30 days, and 30/960 (3.1%) patients had a non-
ischaemic cause of hs-cTnT elevation above the 99th centile
identiﬁed (diagnoses summarised in the online supplementary
appendix). Patients presented to the ED at a median of 2 h
20 min (IQR±228 min) after chest pain onset. Blood was taken
for hs-cTnT at a median of 35 min (IQR±14 min) after patient
arrival.
Diagnostic accuracy of the TRUST ADP
The TRUST ADP classiﬁed 382/960 (39.8%) of patients as at
low risk of fatal or non-fatal AMI (table 3), with a sensitivity for
identifying AMI of 98.8% (95% CI 92.4% to 99.9%) and NPV
of 99.7% (95% CI 98.4% to 100%) and had a similar diagnos-
tic performance for the secondary outcome measure (MACE)
(table 4).
A single patient (0.3%) classiﬁed as low-risk by the TRUST
ADP had an AMI during the initial hospital attendance and
follow-up. This patient was a 78-year-old woman classiﬁed as
low-risk on the m-Goldman score and had a hs-cTnTof 13 ng/L
at presentation. However, a minor hs-cTnT elevation to 20 ng/L
(δ change 27%) occurred on the second hs-cTnT test at 6 h and
was therefore diagnosed with an AMI. The patient was medic-
ally managed and had no further complications.
Undetectable troponin strategies
The diagnostic performance of hs-cTnT limit of detection
cut-off values in patients with a non-ischaemic ECG are shown
in table 4. By using the limit of detection cut-off value of 5 ng/L
for the primary outcome measure (AMI) the sensitivity was
100% (95% CI 94.3% to 100%) and 270/922 (29.3%) of
patients were eligible for early discharge (table 3). However,
using the secondary outcome measure (MACE), three patients
(1.1%) identiﬁed as suitable for discharge using this strategy
required urgent revascularisation (all three were aged in their
40s, two had severe left anterior descending artery disease and
one severe right coronary artery disease). Using the limit of
blank (<3 ng/L) the sensitivity for fatal/non-fatal AMI was
100% (95% CI 94.4% to 100%) and only 7.9% would have
been eligible for early discharge. One patient (1.4%) with a
hs-cTnT <3 ng/L required urgent revascularisation.
Comparison of strategies
The TRUST ADP identiﬁed signiﬁcantly more patients suitable
for immediate discharge at 39.8% vs 29.3% (<5 ng/L) and
7.9% (<3 ng/L) (p<0.001) with a lower false-positive rate for
AMI detection; speciﬁcity 43.3% (95% CI 42.7% to 43.4%) vs
32.0% (95% CI 31.5% to 32.0%) and 8.6% (95% CI 8.1% to
8.6%) respectively, while maintaining a high diagnostic accuracy
for the rule-out of AMI.
DISCUSSION
This study demonstrates that the TRUST ADP for suspected
ACS can successfully identify 40% of patients as low-risk after
just a single hs-cTnT taken at presentation to the ED, with a
NPV of >99.5%. When compared with strategies using
undetectable hs-cTnT, more patients are eligible for early dis-
charge with lower false-positive rates, suggesting this approach
has greater clinical utility. Furthermore, by incorporating clinical
risk stratiﬁcation, the TRUST ADP has improved accuracy in
identifying those who require urgent revascularisation.
Our results suggest that the introduction of this ADP has the
potential to reduce the length of stay for low-risk patients (cur-
rently 14 h in our institution) after a single laboratory-based
troponin and avoid the necessity for two separate blood draws.
Uptake of this protocol may have signiﬁcant beneﬁts for health-
care services worldwide by reducing hospital admission rates,
ED overcrowding, duplication of staff time and resource use.
Furthermore, by using ED physicians to carry out risk-
stratiﬁcation and real-time troponin sampling with 24-h recruit-
ment we have demonstrated that this ADP is truly applicable.
This analysis conﬁrms the results of recent large-scale explora-
tory research that showed undetectable hs-cTnT held promise as
a tool for rule-out of AMI or death.9 However, we demonstrate
that by using MACE (which also includes urgent revascularisa-
tion) missed-event rates of the undetectable troponin strategies
Table 3 Occurrence of fatal/non-fatal AMI and MACE during the
index hospital visit or at 30 days according to index test
AMI No AMI Total
TRUST ADP
Not low risk 79 499 578
Low risk 1 381 382
Hs-cTnT<5 ng/L*
≥5 ng/L 78 574 652
<5 ng/L 0 270 270
Hs-cTnT<3 ng/L*
≥3 ng/L 78 771 849
<3 ng/L 0 73 73
MACE No MACE Total
TRUST ADP
Not low risk 96 482 578
Low risk 1 381 382
Hs-cTnT<5 ng/L*
≥5 ng/L 92 560 652
<5 ng/L 3 267 270
Hs-cTnT<3 ng/L*
≥3 ng/L 94 755 841
<3 ng/L 1 72 73
*922/960 (96%) results are reported for the hs-cTnT detection limits. This was due to
computer error whereby 38 results were only reported as <14 ng/L.
ADP, accelerated diagnostic protocol; AMI, acute myocardial infarction; hs-cTnT,
high-sensitivity troponin T; MACE, major adverse cardiac event; TRUST, Triage
Rule-out Using high-Sensitivity Troponin.
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rise above 1%, this may be unacceptable to the majority of ED
clinicians.22 Therefore, consistent with consensus guidelines,3
we cannot recommend uptake of undetectable hs-cTnT rule-out
strategies in this setting.
Our data suggest that focus move away from strategies that
use a stand-alone single initial undetectable hs-cTn result to
guide discharge decisions, and towards protocols that also
incorporate structured clinical risk assessment. A number of
reports combining these two strategies have been reported
recently and show early promise. For example, the History,
ECG, Age, Risk Factors and Troponin (HEART) score,23 may
enable safe early discharge after a single troponin at presentation
but requires validation with hs-cTn, and the Manchester Acute
Coronary Syndromes (MACS) decision rule,24 has demonstrated
excellent discriminatory power but requires the use of heart-
type fatty acid binding protein in addition to hs-cTn.
Prospective comparison of these strategies is required.
There are some limitations to this study. The inclusion of pre-
dominantly British Caucasian patients may limit the applicability
to international settings. The upper age cut-off of ≥80 years was
chosen for pragmatic reasons. In our institution, patients above
this age are admitted to a separate and dedicated assessment
area. Therefore we recognise that this may affect the applicabil-
ity of TRUST ADP in those >80 years of age.
Patients were only recruited if they had a non-ischaemic ECG
at presentation—thereby reducing the prevalence of MACE in
the study population. Expansion of the inclusion criteria to
include those patients with ECG changes consistent with ACS
would have added little practical value because this group is not
suitable for early discharge anyway. We therefore intentionally
excluded patients with a clear diagnosis of ACS to focus on a
particular group that remains a major diagnostic challenge.
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Key messages
What is already known on this subject?
The use of undetectable high-sensitivity troponin levels and risk
scores in combination with early biomarker testing have recently
been put forward as diagnostic tools aiming to reduce
door-to-discharge times in patients with suspected acute
coronary syndromes. However, a clinically applicable protocol
that allows the discharge of a signiﬁcant proportion of patients
after just a single high sensitivity troponin blood draw at
presentation to the emergency department remains an attractive
yet elusive goal.
What might this study add?
Using a simple clinical risk score, together with the results of a
single high-sensitivity troponin result, the Triage Rule-out Using
high-Sensitivity Troponin accelerated diagnostic protocol, may
enable immediate discharge in up to 40% of patients. This
strategy identiﬁes more patients suitable for early discharge, with
lower false-positive rates than undetectable troponin strategies.
How might this impact on clinical practice?
Chest pain makes up a quarter of medical admissions in the UK.
A diagnostic strategy that prevents unnecessary hospital
admission in a large proportion of this patient group would
have signiﬁcant beneﬁts for healthcare services by reducing
hospital admission rates, emergency department overcrowding,
duplication of staff time and resource use.
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We recognise that the TRUST ADP now requires validation as
part of a multicentre randomised controlled trial. However,
without ﬁrst analysing the safety of this diagnostic strategy
through an observational cohort design, the principle of clinical
equipoise may not have justiﬁed a randomised study design.25
CONCLUSION
The TRUST ADP, which incorporates a structured risk-
assessment and single presentation hs-cTnT blood draw, has the
potential to allow early discharge in 40% of patients with sus-
pected ACS. This ADP has superior clinical utility when com-
pared with undetectable hs-cTnT strategies. Future research
should focus on methodologies that incorporate clinical assess-
ment with hs-cTn testing rather than troponin testing alone.
Twitter Follow Edward Carlton at @eddcarlton
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